Azitra is trading at $0.18, down -5.17% on August 28, 2026, as biotech stocks weaken broadly amid concerns about a hawkish Federal Reserve stance.
- XBI fell 2.31% during regular trading.
- NYSE American compliance restoration, announced August 21 and updated August 27, supported the prior rally but offered no fresh company-specific catalyst.
- The move appears primarily sector-driven, with possible profit-taking after several consecutive advances.